ClinicalTrials.gg
CompletedNCT06708260Updated Oct 5, 2026

A Phase 2 Study to Evaluate the Efficacy and Safety of ENN0403 in Subjects With DME

A Phase 2 interventional study of ENN0403, low dose and ENN0403, high dose in Diabetic Macular Edema (DME), sponsored by EnnovaBio. Completed at 9 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by EnnovaBio · Phase 2, Interventional, and Treatment

Updated Oct 5, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 72 studies in Macular Edema with a site in China — 18 open to participants now, 22 under way, 4 of them phase 3. Macular Edema · China.

Enrollment
47th of 65
60 · median 140
Started
2024
with 9 others
Phase 2
4 of 72
1 open now
Registered
61st of 72
by date

Among the 72 studies in Macular Edema with a site in China, this one is the 47th largest by enrollment of the 65 interventional ones that give a count, is one of 10 that started in 2024, is one of 4 in phase 2, and was the 61st registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

18 of the 72 studies in Macular Edema with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Macular Edema with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, parallel study to evaluate the efficacy and safety of two doses of ENN0403 in subjects with diabetic macular edema (DME). Approximately 60 subjects will be randomized to receive ENN0403 capsule orally once a day at the low dose or high dose with a 1:1 ratio. The study period consisted of up to 2 weeks of screening, 12 weeks of treatment and 2 weeks of follow-up, and the entire trial period was up to 16 weeks.

03

Conditions studied

  • Diabetic Macular Edema (DME)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide written ;
  2. Aware of the entire study process and requirements, understands the importance of medication compliance and completing all assessments on time throughout the study, and agrees to strictly follow the protocol and study procedures, including restrictions on drug combination during the study;
  3. Diagnosis of type 1 or type 2 diabetes mellitus and ≤10.0% with regular use hypoglycemic drugs and stable glycemic control 1 month before screening (at the discretion of the investigator);
  4. The decrease of BCVA is mainly caused byDiabetic Macular Edema in the study eye;
  5. BCVA letter score of ≤ 73 (Snellen 20/40) and ≥ 24 (Snellen 20/320) at screening visit and at baseline. If both eyes meet the inclusion criteria, the study eye will be determined by the investigator from a medical perspective. ( If both eyes meet the inclusion criteria,the eye with poor baseline vision will be selected as the study eye; If the BCVA number is the same, choose the eye with the thicker CRT as the study eye) ;
  6. Optical Coherence Tomography (OCT) foveal CRT at screening measuring ≥300 μm.

Exclusion criteria

Exclusion Criteria:

  1. Study eye with any eye disease or medical history other than DME that causes or may cause irreversible vision loss;
  2. Study eye had glaucoma filtration surgery in the past or may have the surgery during the study;
  3. Study eye had previously undergone vitreoretinal surgery;
  4. Study eye received intraocular hormone drugs within 6 months prior to baseline or periocular or systemic hormone drugs within 3 months prior to baseline;
  5. Any eye received intraocular injection of VEGF within 3 months prior to baseline;
  6. History of idiopathic or uveitis in any eye;
  7. Uncontrolled glaucoma in any eye (defined as IOP ≥25 mmHg after treatment with anti-glaucoma drugs)
  8. History of allergy to the drug or any ingredient, or to any ingredient used during the treatment;
  9. Use of any other investigational drug or device within 3 months or 5 half-lives prior to baseline (whichever is longer);
  10. Other factors considered inappropriate for inclusion in this study at the discretion of the investigator.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    ENN0403 low dose treatment arm

    Drug: ENN0403, low dose

  • Experimental
    ENN0403 high dose treatment arm

    Drug: ENN0403, high dose

Interventions

  • ENN0403 capsules will be orally administered once a day for 12 weeks.

  • ENN0403 capsules will be orally administered once a day for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Change from baseline in Central Retinal Thickness (CRT) at week 12

    Time frame: week 12

Secondary outcomes

  1. Change from baseline in Best Corrected Visual Acuity (BCVA) at week 4, 8, and 12

    Time frame: week 4, 8, 12

  2. Change from baseline in CRT at week 4 and 8

    Time frame: week 4, 8

  3. Incidence of ocular and non-ocular TEAE and SAE

    Time frame: 12 weeks

07

Study locations

9 sites
  • Shijiazhuang People's Hospital
    Shijiazhuang, Hebei 050027, China
  • Hebei Eye Hospital
    Xingtai, Hebei 054001, China
  • Zhengzhou Second Hospital
    Zhengzhou, Henan 450015, China
  • Affiliated Hospital of Shandong Second Medical University
    Weifang, Shandong 261041, China
  • Shanghai Eye Disease Prevention and Treatment Center
    Shanghai, Shanghai Municipality 200040, China
  • Shanxi Eye Hospital
    Taiyuan, Shanxi 030002, China
  • Xian No.1 Hospital
    Xi’an, Shanxi 710002, China
  • Hospital of Chengdu University of TCM
    Chengdu, Sichuan 610075, China
  • Tianjin Medical University Eye Hospital
    Tianjin, Tianjin Municipality 300384, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Aug 2026, 20 months.

Of 32 industry-sponsored phase 2 interventional studies under Macular Edema, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 28. This study's 20 months is above that.

Counting every sponsor, half of 50 studies reached it within 19 months; a quarter within 15 and three quarters within 32.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Dec 2025 → Aug 2026 and completion Feb 2026 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2024
First posted
Nov 27, 2024
StartActual
Dec 12, 2024
Primary completionActual
Aug 12, 2026was Dec 2025
CompletionActual
Aug 20, 2026was Feb 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 5, 2026
Sites
9 sites added, 1 site removed
Show 9 added (9 China)
  • Shijiazhuang People's Hospital · Shijiazhuang, China
  • Hebei Eye Hospital · Xingtai, China
  • Zhengzhou Second Hospital · Zhengzhou, China
  • Affiliated Hospital of Shandong Second Medical University · Weifang, China
  • Shanghai Eye Disease Prevention and Treatment Center · Shanghai, China
  • Shanxi Eye Hospital · Taiyuan, China
  • Xian No.1 Hospital · Xi’an, China
  • Hospital of Chengdu University of TCM · Chengdu, China
  • Tianjin Medical University Eye Hospital · Tianjin, China
Show 1 removed
  • Tianjin Medical University Eye Hospital · Tianjin, China
Oct 5, 2026
Primary completion
Dec 2025→Aug 12, 2026 (actual)
Oct 5, 2026
Study completion
Feb 2026→Aug 20, 2026 (actual)
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Recruiting→Completed
    9 sites added, 1 site removed
    Show 9 added (9 China)
    • Shijiazhuang People's Hospital · Shijiazhuang, China
    • Hebei Eye Hospital · Xingtai, China
    • Zhengzhou Second Hospital · Zhengzhou, China
    • Affiliated Hospital of Shandong Second Medical University · Weifang, China
    • Shanghai Eye Disease Prevention and Treatment Center · Shanghai, China
    • Shanxi Eye Hospital · Taiyuan, China
    • Xian No.1 Hospital · Xi’an, China
    • Hospital of Chengdu University of TCM · Chengdu, China
    • Tianjin Medical University Eye Hospital · Tianjin, China
    Show 1 removed
    • Tianjin Medical University Eye Hospital · Tianjin, China
    Primary completion Dec 2025→Aug 12, 2026 (now actual)
    Study completion Feb 2026→Aug 20, 2026 (now actual)
    + 5 other changes: identifiers, verification date, oversight details, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06708260
Lead sponsor
EnnovaBio
Responsible party
Sponsor
First posted
Nov 27, 2024
Start date
Dec 12, 2024
Primary completion
Aug 12, 2026
Completion
Aug 20, 2026
Last update
Oct 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ENN0403

Start the discussion